Everything below concerns half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
=== Biomedical applications === Quantitative proteomics has distinct applications in the medical field. Especially in the fields of drug and biomarker discovery. LC-MS/MS techniques have started to over take more traditional methods like the western blot and ELISA due to the cumbersome nature of labeling different and separating proteins using these methods and the more global analysis of protein quantification. Mass spectrometry methods are more sensitive to difference in protein structure like post-translational modification and thus can quantify differing modifications to proteins. Quantitative proteomics can circumvent these issues, only needing sequence information to be performed. It can be applied on a global proteome level, or on specifically isolating binding partners in pull-down or affinity purification experiments. Disadvantages, however, in sensitivity and analysis time must be kept in consideration.
=== Pulse vaccination strategy === This strategy repeatedly vaccinates a defined age-cohort (such as young children or the elderly) in a susceptible population over time. Using this strategy, the block of susceptible individuals is then immediately removed, making it possible to eliminate an infectious disease, (such as measles), from the entire population. Every T time units a constant fraction p of susceptible subjects is vaccinated in a relatively short (with respect to the dynamics of the disease) time. This leads to the following impulsive differential equations for the susceptible and vaccinated subjects:
21 July: Health Minister Simeon Brown announces that the New Zealand Government will contribute NZ$82.5 million to the establishment of the University of Waikato's medical school; with the university and private philanthropists contributing the remaining NZ$150 million. The Commerce Commission files criminal charges against electronics retailer Noel Leeming for alleged breaches of the Fair Trading Act 1986. The Gore District Council lifts its "do not drink tap water" directive for Gore. 22 July: Sky TV buys TV3 for a symbolic $1; marking the exit of Warner Bros. Discovery from New Zealand's free-to-air television space. The sale comes into effect on 1 August. New Zealand joins 24 other countries including Australia, the United Kingdom, Canada, Japan and the European Union in issuing a joint statement calling for the Gaza war to end. Representatives of several Jewish and Muslim community groups including the New Zealand Jewish Council and the Federation of Islamic Associations of New Zealand (FIANZ) sign a "harmony and peace accord" to improve interfaith relations amidst the Gaza war. 24 July — The primary school teachers' union, the New Zealand Educational Institute, files for a judicial review at the Wellington High Court of the New Zealand Government's decision to reduce funding for literacy and Māori resource teachers during the 2025 New Zealand budget, which was released in May 2025. 30 July: 36,000 nurses, midwives, and other health workers affiliated with the New Zealand Nurses Organisation strike to protest unsafe staffing levels at Te Whatu Ora facilities.
SPR can be used to study the real-time kinetics of molecular interactions. Determining the affinity between two ligands involves establishing the equilibrium dissociation constant, representing the equilibrium value for the product quotient. This constant can be determined using dynamic SPR parameters, calculated as the dissociation rate divided by the association rate.
Sources: en.wikipedia.org
Humans have known about the heart since ancient times, although its precise function and anatomy were not clearly understood. From the primarily religious views of earlier societies towards the heart, ancient Greeks are considered to have been the primary seat of scientific understanding of the heart in the ancient world. Aristotle considered the heart to be the organ responsible for creating blood; Plato considered the heart as the source of circulating blood and Hippocrates noted blood circulating cyclically from the body through the heart to the lungs. Erasistratos (304–250 BCE) noted the heart as a pump, causing dilation of blood vessels, and noted that arteries and veins both radiate from the heart, becoming progressively smaller with distance, although he believed they were filled with air and not blood. He also discovered the heart valves. The Greek physician Galen (2nd century CE) knew blood vessels carried blood and identified venous (dark red) and arterial (brighter and thinner) blood, each with distinct and separate functions. Galen, noting the heart as the hottest organ in the body, concluded that it provided heat to the body. The heart did not pump blood around, the heart's motion sucked blood in during diastole and the blood moved by the pulsation of the arteries themselves. Galen believed the arterial blood was created by venous blood passing from the left ventricle to the right through 'pores' between the ventricles. Air from the lungs passed from the lungs via the pulmonary artery to the left side of the heart and created arterial blood.
siRNAs can be incorporated into a RNA-induced transcriptional silencing (RITS) complex. An active RITS complex will trigger the formation of heterochromatin around DNA matching the siRNA, effectively silencing the genes in that region of the DNA.
A sarcoma is a rare type of cancer that arises from cells of mesenchymal origin, meaning that sarcomas are cancers of connective tissues such as bone, cartilage, muscle, fat, or vascular tissues. Sarcomas are one of five different types of cancer, classified by the cell type from which they originate. While there are five types under this category, sarcomas are most frequently contrasted with carcinomas which are much more common. Sarcomas are quite rare, making up about 1% of all adult cancer diagnoses and 15% of childhood cancer diagnoses. There are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Common examples of sarcoma include liposarcoma, leiomyosarcoma, and osteosarcoma. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary (or "metastatic") connective tissue tumors, which occur when a cancer from elsewhere in the body (such as the lungs, breast tissue or prostate) spreads to the connective tissue. The word sarcoma is derived from the Greek σάρκωμα sarkōma 'fleshy excrescence or substance', itself from σάρξ sarx meaning 'flesh'.
doi: 10.1530/EJE-18-0608.) ERN / Endo ERN Existing networks or registries and biobanks (Adrenal (MTG1) / Existing networks) European Society of Endocrinology Clinical Practice Guideline on the management of Adrenal Incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors (ESE Clinical Practice Guideline on the management of Adrenal Incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors) European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma (BJS, Volume 104, Issue 4, March 2017, Pages 358–376) ENSAT registry-based randomized clinical trials for adrenocortical carcinoma (Eur J Endocrinol. 2021 Feb;184(2):R51-R59. doi: 10.1530/EJE-20-0800.)
The two substrates of this enzyme are shikimate and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 3-dehydroshikimate, reduced NADPH, and a proton. This enzyme participates in phenylalanine, tyrosine and tryptophan biosynthesis.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.